Search results
Results From The WOW.Com Content Network
The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine. [ 7][ 8]
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [4] [5] The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology ...
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with global headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
(Reuters) -The U.S. Food and Drug Administration approved the expanded use of GSK's respiratory syncytial virus (RSV) vaccine on Friday in adults aged between 50 and 59, making it the first shot ...
The vaccines are the first approved to prevent RSV, which causes around 14,000 deaths in adults aged 65 and older in the U.S. annually, according to government estimates. US CDC OKs use of new ...
The vaccine, named Shingrix, is GSK's top-selling medicine. GSK said the deal with Zhifei is part of its efforts to more than double sales of Shingrix, to more than 4 billion pounds ($4.88 billion ...
Slaoui is a vaccine researcher and, formerly, Chairman of Global Research and Development and Chairman of Global Vaccines at GlaxoSmithKline, where he led the development of five vaccines. [1] General Gustave F. Perna , who served as commanding general of Army Materiel Command , was named Operation Warp Speed chief operating officer .
The new GSK-CureVac mRNA vaccines will target coronavirus variants and could be available in 2022, if approved. GSK and CureVac are making 'next-generation' vaccines that they say can tackle ...